Compass Pathways
announced in February 2026 that its second Phase 3 trial (COMP006) of COMP360 synthetic psilocybin met its primary endpoint in treatment-resistant depression, building on its first positive Phase 3 result.
- Country
- United Kingdom
- Ticker
- CMPS
psilocybin
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Psychedelic medicine & neuropsychiatric biologics | therapeutics-platforms | High | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.